遠(yuan)大醫(yi)藥(yao)集團有限(xian)公司(512.HK)是一家(jia)科(ke)技(ji)創新型(xing)國際化醫(yi)藥(yao)企業(ye)。集團的(de)(de)核(he)心(xin)產品(pin)(pin)涵蓋抗(kang)腫瘤、心(xin)血管(guan)急救制(zhi)劑(ji)及心(xin)腦血管(guan)介(jie)入醫(yi)療器械、抗(kang)病毒抗(kang)感染、呼吸及五(wu)官科(ke)及生(sheng)物(wu)健(jian)康(kang)產品(pin)(pin)和(he)精(jing)品(pin)(pin)原(yuan)料藥(yao)為代表的(de)(de)幾大業(ye)務領(ling)域,形(xing)成了以(yi)“創新壁壘藥(yao)械”、“品(pin)(pin)牌藥(yao)”、“原(yuan)料制(zhi)劑(ji)一體(ti)化”和(he)“健(jian)康(kang)產品(pin)(pin)”為主的(de)(de)四大業(ye)務結構,前(qian)瞻(zhan)性布(bu)局全球創新和(he)科(ke)技(ji)領(ling)先的(de)(de)三(san)條(tiao)賽(sai)道,包括精(jing)準介(jie)入診療,放射性核(he)素偶(ou)聯(lian)藥(yao)物(wu)(Radionuclide–drug conjugate,“RDC”)以(yi)及免疫治療。
集團充分發(fa)揮(hui)“精準和(he)穏健的海內(nei)外業(ye)務拓展能力(li),國(guo)際領先技(ji)術的引進消化落(luo)地(di)能力(li)和(he)優秀的市場推廣銷(xiao)售(shou)能力(li)”,瞄準科技(ji)創(chuang)新前沿領域(yu),以國(guo)際化和(he)科技(ji)創(chuang)新的視野不斷(duan)拓展和(he)落(luo)地(di)新的業(ye)績(ji)增長(chang)點,深(shen)度拓展“心腦血管精準介入診(zhen)療(liao)”、“抗(kang)(kang)腫(zhong)瘤”以及(ji)“抗(kang)(kang)病毒抗(kang)(kang)感染”三個治療(liao)領域(yu)。
集團本著積(ji)極開放的心(xin)態(tai)進(jin)行全(quan)(quan)球化(hua)研(yan)(yan)(yan)(yan)(yan)(yan)(yan)發。全(quan)(quan)球研(yan)(yan)(yan)(yan)(yan)(yan)(yan)發中(zhong)心(xin)已初具雛形,全(quan)(quan)球化(hua)研(yan)(yan)(yan)(yan)(yan)(yan)(yan)發布局已取得階段性成果。集團在全(quan)(quan)球范(fan)圍內(nei)布局了四個(ge)技(ji)術(shu)研(yan)(yan)(yan)(yan)(yan)(yan)(yan)發平臺(tai)和(he)五個(ge)研(yan)(yan)(yan)(yan)(yan)(yan)(yan)發中(zhong)心(xin),前者由RDC技(ji)術(shu)平臺(tai)、DNA研(yan)(yan)(yan)(yan)(yan)(yan)(yan)發技(ji)術(shu)平臺(tai)、mRNA研(yan)(yan)(yan)(yan)(yan)(yan)(yan)發技(ji)術(shu)平臺(tai)及糖組學(xue)研(yan)(yan)(yan)(yan)(yan)(yan)(yan)發技(ji)術(shu)平臺(tai)組成,后者包括武漢光谷(gu)國(guo)際研(yan)(yan)(yan)(yan)(yan)(yan)(yan)發中(zhong)心(xin)(籌建中(zhong))與四個(ge)海外研(yan)(yan)(yan)(yan)(yan)(yan)(yan)發中(zhong)心(xin)(美(mei)國(guo)圣地亞哥研(yan)(yan)(yan)(yan)(yan)(yan)(yan)發中(zhong)心(xin)——免疫治療(liao)(DNA技(ji)術(shu))抗腫瘤、美(mei)國(guo)波士頓研(yan)(yan)(yan)(yan)(yan)(yan)(yan)發中(zhong)心(xin)——精準介入抗腫瘤、比利時研(yan)(yan)(yan)(yan)(yan)(yan)(yan)發中(zhong)心(xin)——mRNA、澳(ao)洲(zhou)研(yan)(yan)(yan)(yan)(yan)(yan)(yan)發中(zhong)心(xin)——抗病毒抗感染)。
未來(lai),集(ji)團將繼續以滿足患者需求(qiu)為中心(xin),以順應市場發(fa)(fa)展(zhan)為方向,以堅持科技創新為原(yuan)動(dong)力,秉承“綜(zong)合(he)優勢、創新壁壘和(he)全球拓(tuo)展(zhan)”的(de)發(fa)(fa)展(zhan)理念,采(cai)用“自主(zhu)研發(fa)(fa)和(he)全球拓(tuo)展(zhan)雙(shuang)(shuang)輪驅動(dong),全球化運營布局和(he)雙(shuang)(shuang)循環(huan)經(jing)營發(fa)(fa)展(zhan)”策略(lve),形成國(guo)內國(guo)際雙(shuang)(shuang)循環(huan)聯動(dong)發(fa)(fa)展(zhan)并相互促進的(de)新格局,致(zhi)力于成為一家受(shou)醫生和(he)患者尊重并還(huan)原(yuan)于社(she)會的(de)科技創新型國(guo)際化醫藥(yao)企業。